News
ABMD
381.02
+0.06%
0.23
UPDATE 5-J&J's medical device sales fall short, cancer drugs seen growing
J&J's medical device sales fall short, cancer drugs seen growing. Sales of psoriasis drug Stelara come in lower than expected. The company's large medical devices business reported $7.82 billion in sales for first quarter. J&J shares were down 1.3% in after-hours trading.
Reuters · 3d ago
UPDATE 4-J&J first-quarter revenue misses as Stelara sales fall short
J&J first-quarter revenue misses as sales of psoriasis drug Stelara sales fall short. Sales of cancer drug Darzalex jumped about 19% to $2.69 billion. J&J's medical devices unit reported $7.82 billion in sales for the quarter. The company reported total revenue of $21.38 billion in the first quarter.
Reuters · 3d ago
UPDATE 5-J&J boosts heart device business in $13.1 bln Shockwave deal
J&J to buy Shockwave Medical in a deal valued at $13.1 billion including debt. J&J is building its cardiac-health-centric medical devices business to help drive growth. Shockwave uses shockwaves to break down calcified plaque in heart vessels. The company has offered $335 per share in cash for Shockwave.
Reuters · 04/05 10:41
US FDA classifies recall of Abiomed's blood pumps as most serious
US FDA classifies recall of Abiomed's blood pumps as most serious. Some Impella Left Sided Blood Pumps by Johnson & Johnson could cause serious injuries or death. The recall is classified as the most serious by the U.S. Health regulator.
Reuters · 03/21 14:46
Is It Too Late to Buy Johnson & Johnson's Stock?
The Motley Fool · 04/28/2023 12:30
More
Webull provides a variety of real-time ABMD stock news. You can receive the latest news about Abiomed Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABMD
ABIOMED, Inc. is a medical technology provider, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Its products are used in the cardiac catheterization lab or cath lab, by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty, or heart surgery procedures. The Company's Impella device portfolio includes the Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices. Its product pipeline includes Impella ECP, Impella XR Sheath, Impella BTR and precardiac. The Impella ECP device is designed for blood flow of greater than three and a half liters per minute. The Impella BTR device is designed to be a heart pump with integrated motors and sensors.